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Abstract 
Background: Getting access to authentic human drug metabolites is an important issue during the drug discovery 
and development process. Employing recombinant microorganisms as whole-cell biocatalysts constitutes an elegant 
alternative to organic synthesis to produce these compounds. The present work aimed for the generation of an 
efficient whole-cell catalyst based on the flavin monooxygenase isoform 2 (FMO2), which is part of the human phase 
I metabolism.
Results: We show for the first time the functional expression of human FMO2 in E. coli. Truncations of the C-terminal 
membrane anchor region did not result in soluble FMO2 protein, but had a significant effect on levels of recombinant 
protein. The FMO2 biocatalysts were employed for substrate screening purposes, revealing trifluoperazine and pro-
pranolol as FMO2 substrates. Biomass cultivation on the 100 L scale afforded active catalyst for biotransformations on 
preparative scale. The whole-cell conversion of trifluoperazine resulted in perfectly selective oxidation to 48 mg (46% 
yield) of the corresponding N1-oxide with a purity >98%.
Conclusions: The generated FMO2 whole-cell catalysts are not only useful as screening tool for human metabolites 
of drug molecules but more importantly also for their chemo- and regioselective preparation on the multi-milligram 
scale.
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Background
Flavin monooxygenases (FMOs) are flavin containing 
enzymes that catalyze substrate oxidation at the expense 
of NADPH and molecular oxygen. FMOs are involved in 
the phase 1 drug metabolism of compounds containing 
soft nucleophiles such as sulfur or nitrogen. Among the six 
known FMO isoforms, the FMO2 isoenzyme—known also 
as the pulmonary FMO—is expressed in lung tissue [1]. In 
humans, two alleles have been described: FMO2*1 is the 
functional full length version that is found in high frequency 
in Sub-Saharan African populations [2–4] and descendants 
from these populations in Hispanics [5] whereas the 
FMO2*2 gene codes for a sequence with a premature stop 
codon that results in a 64 amino acid C-terminal truncation 
and yields non-functional protein FMO2X472 [1].
The substrates typically described for human FMO2*1 
are sulfur derived compounds such as thioureas [6, 7], 
thioetherorganophosphates [6], thiazetazone [8] and 
ethionamide [8, 9]. FMO2 homologues from other mam-
malian species were shown to catalyze also the N-oxi-
dation, e.g. of primary aliphatic alkylamines [10, 11], 
secondary and tertiary aliphatic alkylamines [10] as well 
as a few examples of alicyclic amines like nicotine [12] 
and N-deacetyl ketoconazole [13]. Rabbit FMO2 cata-
lyzed the oxidation of prochlorperazine, desmethylpera-
zine and trifluoperazine [10]. These are phenothiazine 
derived xenobiotics with antipsychotic effects.
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In course of the drug discovery and development pro-
cess, drug metabolites are required for structure elucida-
tion and as analytical references. Furthermore, with the 
introduction of the metabolites in safety testing (MIST) 
guidelines by the US Food and Drug Administration in 
2008, all metabolites present at >10% of the parent com-
pound in the human metabolism have to be subjected to 
toxicity studies [14]. In this context two questions arise: 
Which drug metabolites are formed in the human body 
and how can these compounds be produced in suffi-
cient amounts? Chemical preparation of authentic drug 
metabolites often requires multiple steps including sev-
eral functional group protection and deprotection steps. 
To circumvent this problem, our aim was the generation 
of scalable mimicks of single steps of the phase 1 metab-
olism reactions in vitro. This can be accomplished with 
heterologously expressed human enzymes in a ready-to-
use biocatalyst such as E. coli.
The use of whole-cell catalysts is beneficial in many 
aspects. The enzyme performing the actual biotransforma-
tion does not need to be isolated and purified, which saves 
time and costs. In addition, the half-life of enzyme activity 
can be prolonged because the cell acts as a protective shield 
against e.g. shear forces and organic solvents. As many 
industrially relevant reactions rely on cofactors, whole cells 
constitute an attractive strategy to regenerate these costly 
compounds by exploiting the cell metabolism [15].
A prerequisite for productive whole-cell biocatalysts 
is the efficient expression of the target enzyme. Human 
flavin monooxygenases (hFMOs) are membrane bound 
proteins, a class of proteins that are known to be chal-
lenging targets for recombinant expression in E. coli. 
Therefore, we investigated—among other critical param-
eters—the influence of C-terminal truncation of FMO2*1 
on the overall biocatalyst activity.
Methods
Chemicals and reagents
Ampicillin, benzydamine, ethionamide, (±)-proprano-
lol and trifluoperazine were purchased from Sigma 
Aldrich (Steinheim, Germany) and acetonitrile (ACN) 
from J. T. Baker (Deventer, The Netherlands). Isopro-
pyl β-d-1-thiogalactopyranoside (IPTG) was obtained 
from Biosynth AG (Staad, Switzerland). All other chemi-
cals and buffer components were obtained from Carl 
Roth (Karlsruhe, Germany). NunclonTMΔ surface 24 
well plates were purchased from Nalgene nunc (Pen-
field, USA) and oxygen permeable foils (Gas Permeable 
Adhesive Seals # AB-0718) from Thermo Fisher Scientific 
(Waltham, MA, USA).
Cloning and expression of full length and truncated 
hFMO2
The T1414C mutant of the gene coding for human flavin 
containing monooxygenase 2 (NCBI accession number 
BC005894) was ordered at GenScript (NJ, USA). Plasmid 
DNA was retrieved according to the protocols delivered 
with the genes and used as templates for gene amplifi-
cation using Phusion® High-Fidelity DNA polymerase 
(Finnzymes, Vantaa, Finland) with primers 5′-ATG GCA 
AAG AAG GTA GCT G-3′ and 5′-AAC TAG GAC CAT 
TGA AGT TGG C-3′. This insert was A-tailed with Taq 
polymerase (Thermo Fisher Scientific) and cloned into 
the pEamTA vector as described previously [16]. The 
hFMO2 sequence in construct pEamTA:hFMO2 was 
confirmed by sequencing at LGC Genomics  (Berlin, 
Germany). The construct was then used as a template 
for the construction of truncated hFMO2 proteins. Spe-
cifically, the genes were amplified with Phusion® High-
Fidelity DNA polymerase using forward primer 5′-TTA 
AGC ATA TGG CAA AGA AGG TAG CTG TG-3′ in 
combination with one of the reverse primers as stated 
in Table 1. Subsequently, the fragments were ligated into 
the pMS470 vector via NdeI and HindIII restriction sites, 
transformed into electrocompetent E. coli TOP10 F’ cells 
and the sequences were confirmed by Sanger sequencing 
(LGC Genomics). Finally, electrocompetent E. coli BL21 
(DE3) Gold cells were transformed with plasmid DNA 
to give nFMO2 expression strains. The nFMO2 expres-
sion strains were cultivated as follows: overnight cultures 
[20  mL Luria Bertani (LB) medium supplemented with 
100  µg/mL ampicillin], inoculated with a glycerol stock 
Table 1 Summary of FMO2 truncation variants generated in the present study. The sequence of the reverse primer to 
amplify the truncated gene from the full-length template is shown.
FMO2 variant Reverse primer
FMO2*1X517 (FMO2Δ19) 5′-TTA AGA AGC TTT TAC AAC AGA AAA GAA ACT GAG AAA TTA G-3′
FMO2*1X510 (FMO2Δ26) 5′-TTA AGA AGC TTT TAA TTA GAT GAA TCC TTC AGG GC-3′
FMO2*1X505 (FMO2Δ31) 5′-TTA AGA AGC TTT TAC AGG GCC CGA GTC-3′
FMO2*1X500 (FMO2Δ36) 5´-TTA AGA AGC TTT TAG AGT GGC TTC AGT ATT C-3′
FMO2*1X496 (FMO2Δ40) 5′-TTA AGA AGC TTT TAT ATT CTT TGT TTC TGG GTG AAG-3′
FMO2*1X491 (FMO2Δ45) 5′-TTA AGA AGC TTT TAG GTG AAG ATG GCA TTT C-3′
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sample and grown at 37°C in an orbital shaker) were used 
to inoculate 500 mL LB/ampicillin medium in 2 l baffled 
Erlenmayer flasks (OD600  =  0.05). These main cultures 
were grown at 37°C and 110 rpm to an OD600 of 0.8 and 
subsequently induced with 50  µL of IPTG (1  M). After 
incubation for 24 h at 30°C and 110 rpm, the cells were 
harvested by centrifugation (4,000g, 4°C, 10 min) and the 
pellets were stored at −20°C.
Biomass production
Shake flask cultivations were carried out as follows: A 
glycerol stock of E. coli BL21(DE3)/pMS470nFMO2*1 
was thawed and 20 µL were used to inoculate 20 mL of 
LB medium (containing 100 µg mL−1 ampicillin) in Fal-
con tubes, respectively. The precultures were incubated 
at 90 rpm on a rotary shaker at 37°C overnight. Fresh LB 
cultures (500 mL) with ampicillin (100 µg mL−1) in baf-
fled 2-L Erlenmeyer flasks were inoculated to OD600 0.05 
with the preculture. The main cultures were incubated at 
37°C with shaking at 110 rpm until an optical density of 
0.6–0.8 was reached. FMO2 expression was induced by 
addition of IPTG (1 mM). The cultures were incubated at 
30°C with shaking at 110 rpm for 24 h. Finally, the cells 
were harvested by centrifugation (10  min, 4,000  rpm). 
The cell paste (approximately 2  g of wet cells) was sus-
pended in 8 mL of potassium phosphate buffer (50 mM, 
pH 8.5), and stored at −20°C.
Catalyst preparation in the bioreactor was carried out 
as follows: Cells of E. coli BL21 (DE3) Gold harboring 
the vector with the FMO2*1X510 gene were taken from 
vials stored in liquid nitrogen and streaked on LB agar 
plates containing ampicillin (100 mg/L). The plates were 
incubated at 37°C for 6.5 h. A loop of the resulting cells 
was used to inoculate 10  ×  500  mL baffled flasks each 
containing 100  mL LB media supplemented with ampi-
cillin (100 mg/L). Following incubation for 18 h at 30°C 
with shaking at 200 rpm (orbital shaker, 5 cm radius), the 
pooled pre-cultures were used to inoculate 100 L of LB/
ampicillin (100 mg/L) and Aseol antifoam (0.01% v/v) in 
a Braun Biotech 150  L fermentation vessel. Fermenta-
tion parameters were as follows: temperature 30°C, stir-
ring 150  rpm and airflow 10  L/min. No pH regulation 
was employed. When OD600 reached 0.6–0.8, filter steri-
lized IPTG was added to a final concentration of 1 mM. 
After approx. 24 h cultivation, the biomass was harvested 
by continuous flow centrifugation at 13,000 rpm in a 
Heraeus Contifuge 20RS at 4°C. The resulting cell paste 
(340 g) was then shock frozen in dry ice before storage at 
−80°C.
Cell fractionation
A cell pellet corresponding to 50 OD600 units was resus-
pended in potassium phosphate buffer (50 mM, pH 8.5) 
and disrupted by ultrasonication (6 × 30 s). The resulting 
lysate was centrifuged for 5  min at 5.000×g and 4°C to 
remove cell debris and unbroken cells. In a next centrifu-
gation step (30 min at 10.000×g and 4°C) inclusion bod-
ies, if present, were separated. To recover the membrane 
fractions from E. coli, the cleared lysates were ultra-
centrifuged at 100.000×g and 4°C for 1 h. The resulting 
supernatant contained the cytosolic protein fraction.
Total protein concentrations of each fraction were 
determined by the BCA protein assay (Thermo Fisher 
Scientific), according to the manufacturer´s instructions, 
using bovine serum albumin as standard.
Western blot analysis
50  µg of total protein per lane was separated by SDS-
PAGE under reducing conditions using NuPAGE® 4–12% 
Bis–Tris gel (Life Technologies, Carlsbad, USA). Protein 
bands were transferred onto a nitrocellulose membrane 
(GE Healthcare, Chalfont St Giles, UK) electropho-
retically in a wet blotting system. Immunoblot detec-
tion was performed using an FMO2-specific antibody 
(Abcam, Cambridge, UK, ab171907) according to the 
manual provided by the supplier. The presence of FMO2 
was visualized by staining with nitro blue tetrazolium/5-
bromo-4-chloro-indolylphosphate (NBT/BCIP; Merck, 
Darmstadt, Germany).
Resting cell biotransformation
Frozen cell pellet was thawed and suspended in reaction 
buffer (50 mM potassium phosphate buffer, pH 8.5). The 
cell suspension was equally divided into 24 well plates to 
give an OD600 of approximately 15 based on the final vol-
ume of 1 mL. The reaction was started by addition of 10 µL 
MgCl2 (1 M), 50 µL NADP+ (1 mM), 50 µL trisodiumci-
trate (1 M) and 10 µL substrate in MeOH (100 mM). The 
plate was sealed with oxygen permeable foil and agitated 
at 37°C for 16 h on a Titramax (900 rpm). 500 µL samples 
were drawn and mixed with 500  µL MeOH thoroughly. 
After centrifugation, the supernatant was analyzed by 
HPLC/MS. The optical density of the remaining sample 
was measured in order to determine a correction factor.
Analysis by HPLC–MS
For HPLC measurements, an Agilent Technologies 1200 
Series equipped with G1379B degasser, G1312B binary 
pump SL, G1367C HiP-ALS SL autosampler, a G1314C 
VWD SL UV detector, G1316B TCC SL column oven and 
a G1956B MSD mass selective detector was used. The 
analytes were separated on an Agilent Zorbax SB-C18 
column (1.8  µm; 4.5 ×  50  mm) at 50°C by using aque-
ous eluent (0.1% formic acid) and ACN at a flow of 1.0–
1.2 mL min−1 which was split to 0.6–0.8 mL min−1 before 
the mass selective detector.
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The following gradients were used to separate sub-
strate and products from whole cell conversions: ben-
zydamine (0–2.10  min: 20–70% ACN, 2.10–2.20  min: 
70–90% ACN, 2.20–2.40: 90% ACN, 2.40–2.60  min: 
90–20% ACN); ethionamide (0–1.20  min: 0–70% ACN, 
1.20–2.10 min: 70% ACN, 2.10–3.00: 70–0% ACN); pro-
pranolol (0–3.00  min: 0–100% ACN, 3.00–3.50  min: 
100% ACN, 3.50–4.00: 100–0% ACN); trifluoperazine 
(0–2.50 min: 15–100% ACN, 2.50–3.50 min: 100% ACN, 
3.50–3.51: 100–15% ACN).
Typical example of preparative scale biotransformation
Frozen cell paste was thawed at room temperature and 
re-suspended in a minimal volume of 50 mM potassium 
phosphate buffer pH 8.5. The suspension was held on ice 
until required. Preparative biotransformations were car-
ried out in a total volume of 0.2 L phosphate buffer pH 8.5 
in a 0.5 L baffled flask containing 3.4 g wet weight E. coli 
cells corresponding to an OD600 of 15, 50 mM trisodium-
citrate, 10 mM MgCl2, 50 µM NADP+ and 100 mg triflu-
operazine (final concentration 500 mg/L). The flasks were 
incubated at 37°C with agitation at 110 rpm on an orbital 
shaker (5 cm radius). At various time points aliquots were 
removed and mixed with an equal volume of ACN before 
centrifuging at 13,200  rpm for 2  min. The supernatants 
were analyzed using an Agilent Zorbax SB-C18 column 
(1.8 µm; 4.5 × 50 mm) at 50°C. UV absorption was moni-
tored at 255 nm and the mobile phases consisted of (0.1% 
formic acid) and ACN at a flow of 1.5 mL min−1 (0–2 min: 
40–80% ACN). After 22 h incubation, the biotransforma-
tion yield of N-oxide (Figure 1) reached 89.6%.
The broth was mixed with an equal volume of ethyl ace-
tate and stirred at room temperature for 2 h. The mixture 
was then centrifuged for 1  h at 10,000  rpm in a Sorvall 
JA10 rotor at 4°C. The organic phase was collected and 
the ethyl acetate evaporated under reduced pressure at 
40°C. The residue was dissolved in 2 mL dimethylsulfox-
ide (DMSO) and this solution contained 95 mg N-oxide 
according to HPLC analysis.
The crude product was mixed with 2  mL ACN and 
2  mL water and filtered through a PTFE syringe filter. 
The filtrate was pumped directly onto the RP18 chro-
matography column concurrently with a 9-fold larger 
volume stream of an aqueous solution (0.025% v/v) of 
trifluoroacetic acid (TFA). The conditions for prepara-
tive HPLC were: stationary phase: Chromolith prep. 
RP18e 100 ×  25  mm (Merck, 1.25252.0001); solvent A: 
aqueous TFA 0.025%; solvent B: ACN; gradient: 0–5 min 
10% B, 45 min 40% B; flow rate of 50 mL/min; room tem-
perature; detection at 259 nm; fraction size 50 mL. The 
product eluted between 24 and 25% B. All fractions were 
analyzed by LC/MS–UV. Fractions containing >95% 
of product (relative LC/UV peak area) were combined, 
the solvents were evaporated under reduced pressure to 
about 50 mL and finally dried by lyophilisation overnight. 
The product, 48  mg 1-methyl-4-(3-(2-(trifluoromethyl)-
10H-phenothiazin-10-yl)propyl)piperazine 1-oxide, was 
obtained in 46% isolated yield >98% purity (HPLC/full 
diode array detection) 1H and 13C NMR spectra were 
recorded on a Bruker Avance III instrument (1H NMR 
600.13 MHz, 13C NMR 150.9 MHz).1H NMR (600 MHz, 
DMSO-d6) δ 7.36 (d, J  =  8.0  Hz, 1H, H-4″), 7.28–7.21 
(m, 3H, H-8″/1″/3″), 7.18 (d, J = 7.6 Hz, 1H, H-6″), 7.08 
(d, J = 8.2 Hz, 1H, H-9″), 7.00 (t, J = 7.5 Hz, 1H, H-7″), 
4.19 (t, J = 7.5, 2H, H-3′), 3.75 (m, 4H, H-2/6) 3.53 (s, 3H, 
H-7), 3.20 (d, J =  12.1  Hz, 2H, H-3), 3.03 (s, 1H, H-5), 
2.87 (s, 2H, H-1′), 1.96–1.90 (m, 2H, H-2′).13C NMR 
(151 MHz, DMSO-d6) δ ppm, 23.15 (C-2′), 44.61 (C-3′), 
46.31 (C-5), 46.56 (C-3), 53.68 (C-1′), 56.59 (C-7), 62.55 
(C-6), 62.57 (C-2), 112.39 (C-1″), 116.85 (C-9″), 119.54 
(C-3″), 123.48 (C-5″a), 123.71 (C-7″), 127.89 (C-6″), 
128.21 (C-4″), 128.40 (C-8″), 129.05 (C-2″), 124.55 
(C-11″), 130.01 (C-4″a), 144.24 (C-9″a), 145.81 (C-10″a).
Results and discussion
Design of FMO2 truncations
Up to now, functional production of human FMO2*1 was 
achieved by baculovirus driven expression in Sf9 [9] and 
Tricoplusia ni insect cells [1]. However, these expression 
systems are not suitable for preparative biotransforma-
tions. FMO3 and FMO5 have been successfully expressed 
in E. coli [17–19] in contrast to human FMO2. In our 
hands, FMO2*1 showed very little expression in E. coli 
BL21 compared to isoforms 3 and 5 [20]. Krueger et al. 
investigated truncated versions of rabbit FMO2*1 in 
which the protein was expressed lacking the C-terminal 
membrane anchor in an attempt to solubilize the protein 
[21]. Similarly, truncated human FMO3 was expressed in 
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E. coli. Whereas in the case of rabbit FMO2*1X510 the 
protein was found in the membrane fraction, FMO3X516 
was reported to be cytosolic [22].
In this study, six truncated versions of FMO2*1 were 
designed and expressed in E. coli. FMO2*1X517 (Δ19) 
resembles FMO3X516 and according to the mem-
brane domain prediction programs TopRed and MPex 
the membrane anchor is not fully removed like in 
FMO2*1X510 (Δ26). In addition to the Δ19 and Δ26 
variants, FMO2*1 truncations lacking 31, 36, 40 and 45 
amino acids were investigated herein (see Table 1).
Expression and localization of full‑length and truncated 
FMO2*1
To investigate the subcellular location of the generated 
FMO2*1 truncations, Western blot analyses of cytosolic 
and membrane protein fractions with FMO2 specific 
antibodies were conducted.
As shown in Figure  2, removing amino acids from 
the C-terminus of FMO2*1 did not affect the mem-
brane-bound nature of the corresponding proteins. Like 
full-length FMO2*1, all the generated FMO2*1 trun-
cations were detected in the membrane fraction, but 
not in the cytosolic one or in inclusion bodies (data not 
shown). This is in accord with studies of FMO2Δ64 
(FMO2*1X472), the product of the major human FMO2 
allele: It was shown that the removal of the 64 amino acid 
residues had no effect on protein targeting, FMO2*1X472 
being still attached to the membranes of the endoplas-
matic reticulum in T. ni insect cells [1]. Also in the case 
of rabbit and monkey FMO2, C-terminal truncations did 
not change the subcellular localization in comparison 
to the full-length enzyme [12, 23]. These findings and 
evidence from homologous enzymes [21] suggest that 
not only the C-terminal part is essential for membrane 
association. When the amino acid sequence of FMO2*1 
is analyzed by transmembrane domain prediction pro-
grams (MPEx, Scampi-msa and OCTOPUS), the N-ter-
minus is also predicted to be a membrane anchor (amino 
acid 4-19). The amino acids 4–34 constitute the puta-
tive flavin adenine dinucleotide (FAD) binding domain 
including the GxGxxG motif for FAD-binding [24]. Con-
sequently, N-terminal truncation is not an option to solu-
bilize hFMOs.
Although the C-terminal truncations did not result 
in soluble FMO2 protein, they had a pronounced effect 
on the levels of recombinant protein as assessed from 
Western blot analysis (Figure  2). In comparison to the 
full length protein, the production of the truncation 
FMO2*1X510 was increased. All other truncated FMO2 
proteins were produced in lower amounts, expression 
levels for the shortest truncations (FMO2*1X496 and 
FMO2*1X491) being even below the detection limit. 
As the latter ones also did not show activity in whole-
cell conversions of ethionamide (see below), it might be 
concluded that these variants were not expressed at all. 
Most probably, removing certain stretches of the pro-
tein impairs proper protein folding and in further conse-
quence the protein stability.
Catalytic activities of full‑length and truncated FMO2*1
To investigate the activity of the generated FMO2 cata-
lysts, whole-cell conversions of ethionamide were per-
formed. Ethionamide is a second-line drug for the 
treatment of tuberculosis. Its antibiotic effect emerges 
after sulfur oxidation, a reaction that is also catalyzed 
by human FMO2*1 (Figure 3b) [8, 9]. Expression strains 
of FMO2*1 and its truncated versions were cultivated in 
shake flasks and used for whole cell biotransformations 
of ethionamide.
Prior to the biotransformations described in the follow-
ing, the previously used conditions [20] were optimized. 
The most significant parameter appeared to be the 
amount of biocatalyst: In order to avoid potential limi-
tations of the oxygen supply (which is the co-substrate), 
decreasing cell densities were studied. Cell densities ≤10 
and ≥50 (OD600) at reaction start resulted in decreased 
conversions as compared to ODs of approximately 20. 
Since the specific productivity is reciprocally correlated 
to the biocatalyst amount, a cell density of 15 was consid-
ered to be optimal for FMO mediated biotransformations 
and used for all transformations described herein.
E. coli whole-cell catalysts were frozen and thawed 
before use in order to reach a permeabilized state to 
Figure 2 Western blot analysis of full-length and truncated FMO2*1 
in the membrane fraction of recombinant E. coli strains. 50 µg total 
protein of the membrane preparation of the empty vector con-
trol (pMS470, 1), FMO2*1 (2), FMO2*1X517 (3), FMO2*1X510 (4), 
FMO2*1X505 (5), FMO2*1X500 (6), FMO2*1X496 (7), FMO2*1X491 (8) 
were loaded, respectively. (Std.) PageRuler Prestained Protein Ladder 
(Thermo Fisher Scientific). The blot was probed with anti-hFMO2 
antibody.
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ensure efficient transport of substrate, product and cofac-
tor. Compared to fully disintegrated cells, the enzymes 
involved in NADPH formation retain their functionality 
and may be exploited for cofactor recycling.
The productivity of the strains for ethionamide metabo-
lization was assessed by comparison of product amounts 
formed after 16  h of reaction time (Figure  3). The bio-
catalysts based on FMO2*1 and FMO2*1X517 only 
showed substrate conversions <10%. The ethionamide 
oxidation was significantly more efficient employing the 
FMO2*1X510 and FMO2*1X505 catalysts, yielding sub-
strate conversions of 70 and 30%, respectively. Consist-
ent with the low or non-detectable levels of recombinant 
protein, catalysts based on the shorter FMO2 variants 
(≤FMO2*1X500) did not show substantial ethionamide 
conversions (Figure 3a).
Identification of new hFMO2 substrates
Human pulmonary FMO was almost exclusively 
described to oxidize sulfur containing compounds to 
their sulfoxides, whereas their animal model homologues 
also oxidized nitrogens of various amines. Due to the 
high similarity between these enzymes, we hypothesized 
that the substrate scope of human FMO2*1 is likely to be 
broader than reflected in the literature. A small panel of 
active pharmaceutical ingredients containing sulfur and 
nitrogens of different chemical ambience were screened 
as FMO2*1 substrates. Particularly high activity has been 
observed with benzydamine, a typical FMO substrate 
(hFMO1 and hFMO3) [24]. It is a nonsteroidal anti-
inflammatory drug with additional analgesic and local 
anesthetic properties, used in the treatment of mouth 
and throat infections [25].
We incubated benzydamine with resting cells contain-
ing FMO2*1. After 16 h of reaction time, 100% conversion 
was obtained in whole-cell biotransformations employing 
E. coli cells expressing the full-length FMO2*1 protein. 
Benzydamine has also been reported as a substrate of the 
FMO2 from cynomolgus macaques, which shares a 98% 
sequence identity with human FMO2*1 [26]. Interest-
ingly, in contrast to the ethionamide biotransformations, 
the catalysts based on FMO2*1X510 and FMO2*1X505 
did not show an improved performance in comparison 
to the full-length FMO2*1 catalyst, even at shorter reac-
tion time (4  h). The catalyst FMO2*1X517, although 
showing the same conversions rates for ethionamide as 
FMO2*1, displayed significantly less activity in the case 
of benzydamine (Figure 4). The detected metabolite was 
the product of a single oxidation as assessed by mass 
selective detection. Benzydamine contains three nitro-
gen atoms which raised the question of regioselectivity. 
One of the three nitrogens in benzydamine is part of an 
imidic acid functionality and less likely to be oxidized by 
FMOs compared to the other two tertiary amines. On 
the one hand, dimethylaniline was found to be oxidized 
by rabbit FMO2 [10], indicating that tertiary amines are 
FMO2 substrates. Imipramine and chlorpromazine bear 
dimethylated amines on an aliphatic chain and perfectly 
resemble benzydamine in the respective part of the mol-
ecule, but these two compounds were described as non-
substrates of pulmonary FMO [10, 27]. In literature, 
indirect methods such as oxygen or NADPH consump-
tion assays were typically used to determine whether a 
compound is a substrate or not, but these methods do 
not allow assignment of the site of oxidation. Structure 
elucidation of the metabolites is indispensable in order 
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to understand the true substrate specificity of metaboliz-
ing enzymes, and, in the long run, to be able to predict 
the metabolites of new xenobiotics [28]. We up-scaled 
the screening reaction and used 50  mg of benzydamine 
as a substrate for FMO2*1X510. The crude product was 
analyzed by NMR (Additional file 1). The dimethylated 
amine had been oxidized to the respective N-oxide, as 
judged by a shift of the methyl signals and the methylene 
adjacent to the aliphatic nitrogen. By contrast, lidocaine, 
which is a diethyl amine, was not a substrate under the 
screening conditions used herein.
Another compound, which we found to be metabolized 
by hFMO2, was propranolol. Propranolol is used as a 
β-adrenergic blocking agent for the treatment of angina 
pectoris, hypertension and abnormal heart rhythms. The 
role of propranolol metabolism with cytochrome P450 
enzymes (CYP) is well studied whereby the naphthaline 
part of propranolol is oxidized by CYP2D6 or N-dealkyla-
tion occurs [29, 30]. In contrast, little attention has been 
paid to FMO mediated propranolol metabolism. N-oxi-
dation of this compound was only described for hepatic 
porcine FMO [31], but not for the pulmonary FMO iso-
enzyme until now. We detected significant conversion of 
propranolol to a product mixture consisting of at least 
four compounds. Each compound showed the mass of 
a mono-oxidation product. Our attempts to elucidate 
the chemical structure of the major metabolite by NMR 
were unsuccessful due to its decomposition in the NMR 
solvent. The spectra indicated, however, that N-hydrox-
ylamine propranolol was not the primary product. Based 
on mass selective detection, also N-dealkylation can 
be ruled out and nitrone formation seems unlikely. As 
described by Baughman et  al. for propranolol conver-
sions with hepatocytes of various species [32], the isopro-
pyl part can be oxidized and one could speculate that this 
reaction may have been catalyzed by FMO2. It remains 
to be clarified if the product mixture was a result of low 
metabolite stability in solution, rearrangement reactions 
or FMO2 selectivity towards propranolol.
FMO2 based metabolite production on multi mg‑scale
Screening for compounds that are targeted by FMO2 in 
human drug metabolism further revealed trifluopera-
zine as an hFMO2 substrate. Trifluoperazine is a mem-
ber of the phenothiazine family of drugs and it has one 
sulfur and three nitrogen atoms in its chemical structure. 
The FMO2 expressing strains described herein exhib-
ited excellent activities for the oxidation of this drug to 
a single, mono-oxidized metabolite (Figure 5). Based on 
literature knowledge, the prediction whether the sulfur 
or one of the three nitrogens had been oxidized was not 
trivial, because human FMO2 has—to this end—been 
described as sulfur oxidizing (thioureas, thioetheror-
ganophosphates, thiazetazone, ethionamide [6–9]). By 
contrast, FMO2 homologues from other mammals were 
shown to act on amines [10–13]. Poulson et al. ascribed 
the oxidation of three perazine derivatives by rabbit 
FMO2 to N-oxidation, however, the specific site of oxida-
tion was not elucidated [10].
In order to unambiguously determine the chemical 
structure of the trifluoperazine metabolite produced by 
FMO2*1 and its truncated versions, 50  mg of the com-
pound were subjected to biooxidation using E. coli cells 
grown in a bioreactor at the 100 L scale and the product 
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was isolated and characterized by NMR. Compared to 
the parent compound trifluoperazine, the spectra of the 
phenothiazine and propane part remained identical in 
the metabolite, which ruled out sulfur and phenothia-
zine nitrogen oxidation. However, there was a significant 
change in the piperazine part of the metabolite. Whereas 
the ring-methylene groups in trifluoperazine gave a very 
broad and undefined peak due to the high flexibility of 
the alicyclic ring, the metabolite signals were defined 
well. Also peak shifts that are similar to those seen 
between N-methyl-morpholine and its N-oxide indicate 
N-oxidation of the piperazine ring. Summarizing, these 
spectra show that trifluoperazine had been oxidized at 
the methylated nitrogen of the piperazine ring. Chemical 
oxidation of trifluoperazine with, e.g. hydrogen peroxide 
or sodium periodate at room temperature lead to a prod-
uct mixture without even traces of the human metabolite 
(data not shown), which is in accordance to a literature 
report [33]. In contrast, recombinant FMO2 leads to fully 
chemo- and regioselective oxidation in quantitative yield. 
This result underlines the importance of having tools 
available allowing for the simple and straightforward syn-
thesis of authentic human drug metabolites.
Conclusions
Human flavin monooxygenase 2 (hFMO2) was success-
fully used in form of E. coli based whole-cell catalysts. 
Solubilizing membrane associated enzymes by removal 
of their membrane anchor(s) is a strategy to afford higher 
enzyme levels. In case of hFMO2, N-terminal truncation 
would remove the FAD binding site and C-terminal trun-
cation did not affect protein localization, as reported 
herein. Although hFMO2*1X510 remained attached to 
the membrane fraction, a positive effect on its expression 
level translated in a whole-cell biocatalyst with increased 
activity. The thus generated catalysts were used on the 
one hand to investigate the substrate scope of the FMO2 
enzyme beyond literature known substrate structures. 
On the other hand, the synthetic utility of recombinant 
human FMO2 for metabolite preparation was finally 
demonstrated by the selective oxidation of a substrate 
with several soft nucleophiles (trifluoperazine).
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